AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

2.850

0.000

Volume:40.84K

Turnover:115.20K

Market Cap:233.39M

PE:13.73

High:2.850

Open:2.850

Low:2.800

Close:2.850

52wk High:6.500

52wk Low:2.040

Shares:81.89M

Float Shares:67.00M

Volume Ratio:0.37

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.208

EPS(LYR):0.208

ROE:8.20%

ROA:-1.73%

PB:0.60

PE(LYR):13.73

Loading ...

Overview Company News Filings

Mayne Pharma - Confirms That CEO Is Not Involved in Any Remuneration Decisions Regarding Issue of Incentives to Him

THOMSON REUTERS

Mayne Pharma Group Ltd-Further Details Re Equity Instruments to Be Issued to CEO

THOMSON REUTERS

BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 Million

Mayne Pharma Group Reports Higher Fiscal Q3 Revenue

MT Newswires Live

Stock Track | Mayne Pharma Group Soars 5.58% Intraday on Strong Revenue, Tariff Immunity and Buy-Back Plans

Mayne Pharma Group Ltd: No Material Earnings Impact From US Tariff Proclamation on 7 April

THOMSON REUTERS

Mayne Pharma Group - Continues to Examine Capital Allocation Strategies, May Include on-Market Share Buy-Back

THOMSON REUTERS

Maywood Acquisition Closes $100 Million IPO

MT Newswires Live

BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs

BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs

Mayne Pharma - Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation

THOMSON REUTERS

Mayne Pharma Group Ltd - Myx Expects No Material Impact From US S232 Tariffs

THOMSON REUTERS

Mayne Pharma Group - Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products

THOMSON REUTERS

Mayne Pharma - Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/MYX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":2.85,"timestamp":1790921520000,"preClose":2.85,"halted":0,"volume":40842,"delay":0,"changeRate":0,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"Market Closed","change":0,"latestTime":"10-02 16:12:00 AEST","open":2.85,"high":2.85,"low":2.8,"amount":115195,"amplitude":0.017544,"askPrice":2.94,"askSize":96,"bidPrice":2.82,"bidSize":9154,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.85,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":0.3740246898230885,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":2.85,"auctionPrice":2.85,"auctionVolume":540,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921403461}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":0.3740246898230885,"shares":81890887,"dividePrice":0,"high":2.85,"amplitude":0.017544,"preClose":2.85,"low":2.8,"week52Low":2.04,"pbRate":"0.60","psRate":"0.61","week52High":6.5,"institutionHeld":0,"latestPrice":2.85,"committee":0.979243,"eps":0.207588,"divideRate":0,"volume":40842,"delay":0,"ttmEps":0.207588,"open":2.85,"prevYearClose":3.11,"prevWeekClose":2.81,"prevMonthClose":2.92,"prevQuarterClose":2.92,"fiveDayClose":2.81,"twentyDayClose":3.11,"sixtyDayClose":2.87,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631752031","title":"Mayne Pharma - Confirms That CEO Is Not Involved in Any Remuneration Decisions Regarding Issue of Incentives to Him","url":"https://stock-news.laohu8.com/highlight/detail?id=2631752031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631752031?lang=en_us&edition=fundamental","pubTime":"2026-04-30 06:23","pubTimestamp":1777501382,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE8K62YS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631312520","title":"Mayne Pharma Group Ltd-Further Details Re Equity Instruments to Be Issued to CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2631312520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631312520?lang=en_us&edition=fundamental","pubTime":"2026-04-30 06:23","pubTimestamp":1777501382,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE8K62YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631556330","title":"BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631556330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631556330?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:23","pubTimestamp":1777425830,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 MillionApril 29  - Mayne Pharma Group Ltd MYX.AX:QTRLY  UNDERLYING EBITDA OF -A$1.4 MILLIONNO MATERIAL EARNINGS IMPACT FROM US TARIFF PROCLAMATION ON 7 APRILQTRLY REVENUE A$85.2 MILLIONCONTINUES TO EXAMINE CAPITAL ALLOCATION STRATEGIES, MAY INCLUDE ON-MARKET SHARE BUY-BACKFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41B152:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553185","title":"Mayne Pharma Group Reports Higher Fiscal Q3 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553185?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:41","pubTimestamp":1777423296,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150217046","title":"Stock Track | Mayne Pharma Group Soars 5.58% Intraday on Strong Revenue, Tariff Immunity and Buy-Back Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1150217046","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150217046?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:17","pubTimestamp":1777421842,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd's stock surged 5.58% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical company.The sharp rise appears to be driven by several...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530545","title":"Mayne Pharma Group Ltd: No Material Earnings Impact From US Tariff Proclamation on 7 April","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530545?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:33","pubTimestamp":1777419228,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B152:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530528","title":"Mayne Pharma Group - Continues to Examine Capital Allocation Strategies, May Include on-Market Share Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530528?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:33","pubTimestamp":1777419228,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B152:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230683","title":"Maywood Acquisition Closes $100 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230683","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230683?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:26","pubTimestamp":1776284780,"startTime":"0","endTime":"0","summary":"Maywood Acquisition  said late Wednesday it has completed its initial public offering of 10 million units at $10 per unit, resulting in gross proceeds of $100 million.Its units are listed on Nasdaq under the symbol \"MYXXU\".Each unit consists of one Class A ordinary share, one right entitling the holder to receive one-fourth of one Class A ordinary share upon the completion of an initial business combination, and one warrant to purchase one Class A ordinary share for $11.50 per share, subject to adjustment, according to the company.Once the securities comprising the units begin trading separately, the ordinary shares, rights and warrants are expected to be listed on Nasdaq under the symbols \"MYX,\" \"MYXXR\" and \"MYXXW,\" respectively.An aggregate of $100 million from IPO net proceeds and a simultaneous private placement of units was placed in a trust, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPCX","BK7096","MYX.AU","BK7508","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625985237","title":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625985237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625985237?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:15","pubTimestamp":1775528150,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 TariffsApril 7  - Mayne Pharma Group Ltd MYX.AX:MYX EXPECTS NO MATERIAL IMPACT FROM US S232 TARIFFSENTIRE US DERMATOLOGY GENERICS PORTFOLIO EXPECTED TO BE EXEMPT FROM TARIFFS UNDER PROCLAMATIONNO MATERIAL IMPACT EXPECTED FOR MAYNE PHARMA'S WOMEN'S HEALTH PORTFOLIO FROM US S232 TARIFFSSEVERAL OF COMPANY'S BRANDED DERMATOLOGY PRODUCTS MAY BE SUBJECT TO NEW SECTION 232 TARIFFSMINIMAL IMPACT EXPECTED IN SALISBURY, SOUTH AUSTRALIA MANUFACTURING FACILITY AS MOST EXPORT PRODUCTS TO US ARE GENERIC PRODUCTSFurther company coverage: MYX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625598338","title":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625598338","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625598338?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:04","pubTimestamp":1775523848,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs** Mayne Pharma MYX.AX gains as much as 4.7% to A$2.45, highest since April 2** Stock marks biggest intraday pct gain since April 1** Co expects no material impact to FY27 earnings profile from New Section 232 tariff proclamation announced by Donald Trump** Trump signed executive order imposing 100% tariffs on branded pharma products imported into U.S. unless makers agree to government drug pricing deals or commit to making their products domestically** YTD, MYX down 21.5%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q01Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625979600","title":"Mayne Pharma -  Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625979600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625979600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944600","title":"Mayne Pharma Group Ltd -  Myx Expects No Material Impact From US S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625600102","title":"Mayne Pharma Group -  Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600102?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625460018","title":"Mayne Pharma -  Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625460018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625460018?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}